IND Readiness

IND Readiness Assessment Before Submission Risk Becomes Delay.

A structured pre-submission review for biotech and pharma teams across nonclinical, CMC, clinical protocol, starting-dose, and safety dimensions — surfacing missing evidence, likely FDA question areas, and clinical hold risk signals before the Investigational New Drug application goes in.

Check IND ReadinessView Readiness Criteria

An IND is not just a document package. It is a regulatory argument.

What this IND readiness assessment helps with

  • Request an AI-assisted IND readiness assessment connected to Alenvo.
  • Built for biotech, pharma, preclinical, clinical, translational, and regulatory teams preparing for IND submission.
  • Helps structure evaluation of nonclinical readiness, CMC readiness, clinical protocol risk, starting-dose rationale, safety margins, FDA question areas, and clinical hold risk indicators.
  • Outputs may include an IND readiness score, completeness map, risk prioritization, likely FDA questions, clinical hold risk signals, and remediation priorities.
  • Supports expert review and planning. Does not replace expert judgment.

At a glance

Evaluates IND package readiness before submission.
Separates completeness from regulatory risk.
Highlights potential FDA question areas.
Surfaces clinical hold risk indicators.
Supports expert review and planning.
Connected to Alenvo's AI-assisted regulatory workflows.

The problem

IND delays usually come from gaps teams could have identified earlier.

Clinical holds, information requests, and review delays rarely come from a single missing document. They come from rationale that doesn't connect across nonclinical, CMC, and clinical domains.

  • Incomplete nonclinical package
  • Weak toxicology rationale
  • Missing safety margins
  • CMC gaps
  • Unclear starting dose rationale
  • Incomplete investigator brochure
  • Protocol risks
  • Poorly explained translational bridge
  • Unclear risk mitigation plan

An IND is not just a document package. It is a regulatory argument.

The approach

An Alenvo-connected IND readiness assessment.

The workflow helps teams evaluate the IND package across regulatory dimensions — not just completeness, but the strength of the underlying regulatory argument.

  • Whether the package is complete
  • Where FDA may ask questions
  • What could delay clearance
  • What could increase clinical hold risk
  • Which gaps are high priority
  • What needs to be addressed before submission

Definitions

IND readiness assessment
A structured evaluation of an IND package across nonclinical, CMC, clinical, safety, and starting-dose dimensions to identify gaps and regulatory risk before submission.
Clinical hold risk
The likelihood that FDA will place a proposed study on full or partial clinical hold based on signals such as inadequate safety justification, unresolved toxicology questions, or protocol design issues.
FDA question prediction
An assessment of where FDA reviewers are most likely to raise questions or information requests during IND review, based on package contents, rationale strength, and cross-domain consistency.
Completeness vs risk
Two separate measures. Completeness asks whether the required content is present. Risk asks whether the content is strong, consistent, and well-justified.

IND readiness categories

The assessment structures evaluation across six categories that together drive IND clearance probability.

Nonclinical Readiness

  • Pivotal tox study completeness
  • Genotoxicity package coverage
  • Translational bridge to clinical dose

CMC Readiness

  • Drug substance characterization
  • Stability data for proposed shelf life
  • Manufacturing process consistency

Clinical Protocol Readiness

  • Inclusion/exclusion rationale
  • Stopping rules and dose escalation
  • Endpoint and safety monitoring plan

Investigator Brochure Readiness

  • Nonclinical summary alignment
  • Risk and adverse event sections
  • Reference safety information clarity

Safety Margin / Starting Dose Rationale

  • NOAEL-to-HED conversion
  • Allometric scaling assumptions
  • MABEL vs NOAEL justification

FDA Question Prediction

  • Tox study design gaps
  • Missing CMC justifications
  • Protocol-safety mismatches

Completeness and risk are not the same thing.

A package can be mostly complete but still high-risk if key evidence is weak, poorly justified, or misaligned across nonclinical, CMC, and clinical domains.

The assessment separates the two so teams can see where to add content and, separately, where to strengthen rationale.

Completeness

92%

Content present

Regulatory risk

High

Rationale weak

Example: a nonclinical package is documented but the toxicology justification doesn't support the proposed starting dose. Complete, but high-risk.

Decision-support outputs: clinical hold risk and CMC readiness signals

IND readiness score
Completeness vs risk distinction
Clinical hold risk indicators
Missing evidence map
FDA likely question list
High-priority remediation items
Submission confidence level
Cross-domain risk connections

Who the IND readiness review supports — from pre-IND meeting preparation through submission

Biotech foundersRegulatory affairs teamsPreclinical teamsTranslational medicine teamsClinical development teamsConsultants preparing INDsInvestors evaluating IND-stage companies

Before and after: from manual checklists to structured nonclinical IND-enabling studies review

Before

  • Manual checklist
  • Siloed reviews
  • Unclear risk prioritization
  • Late-stage surprises
  • Hard-to-explain gaps

After

  • Structured readiness view
  • Prioritized risk ranking
  • FDA question prediction
  • Clear remediation plan
  • Executive-ready summary

Find the gaps before FDA finds them.

Request an IND readiness assessment connected to Alenvo and review submission risk before your package goes in.

Check IND Readiness

Request an IND Readiness Assessment

No confidential information is required. Share only what is appropriate for an initial conversation.